Drug Database
NA

naltrexone (Exopio)

✓ Approved

Nanodaru · OPRK1 · 小分子

什么是 naltrexone?

naltrexone 是一种小分子,由Nanodaru研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Exopio
公司Nanodaru
药物类别小分子
分子靶点OPRK1, OPRM1
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

naltrexone 作用于 2 个分子靶点:

OPRK1opioid receptor kappa 1 (KOR1, OPRK)
OPRM1opioid receptor mu 1 (MOR1, LMOR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

naltrexone 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersAlcoholism✓ Approved
Psychiatric disordersDrug dependence✓ Approved

相关研究文献

PubMedJAMA network open2026-11-18

Cost-Effectiveness of Alcohol Use Disorder Treatment for Alcohol-Associated Liver Disease.

Gerber Annabel A, Agyekum Alice A, Yang Jeong Yun JY, Varghese Sheril S et al.

Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality and liver transplant. Combined behavioral interventions (CBI) and medications for alcohol use disorder (MAUD) are underutilized. Thus, it is critical to identify optimal therapeutic and cost-effective windows for CBI and MAUD in patients with ALD at earlier fibrosis stages. To evaluate the cost-effectiveness of naltrexone and CBI in preventing cirrhosis in patients with ALD compared with no treatment. This economic evaluation used a Markov state-transition model simulating lifetime disease progression and health care costs associated with ALD. The simulated patient cohort began at 45 years of age with active AUD and stage 3 fibrosis (F3) and could experience progression to compensated or decompensated cirrhosis. All patients were assumed to complete a 16-week course of naltrexone along with 52 weeks of CBI. Primary outcomes included total health care cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Secondary outcomes included liver-related mortality and progression to compensated and decompensated cirrhosis. Scenario and sensitivity analyses were performed to determine outcomes at earlier stages and with varied cost and model parameters. Without intervention, 61% of the cohort died from liver-related causes, 88% developed compensated cirrhosis, and 66% of those experienced progression to decompensated cirrhosis, with a lifetime cost of $79 799 per person. With treatment initiated at F3, liver-related mortality was reduced to 58%, lifetime compensated cirrhosis to 87%, and lifetime progression to decompensated cirrhosis to 62%, with a lifetime cost of $78 673. The treatment strategy dominated because the lifetime costs were lower and more QALYs were gained when compared with untreated natural history. Treatment was preferred in sensitivity analyses at relapse rates to 100% and adherence greater than 0%, in scenario analyses when treatment was initiated at stages F2 and F1, and for the models including societal and AUD costs. In this economic evaluation of AUD treatment for patients with ALD, treating patients with ALD with naltrexone and CBI at F3 saved cost and was more effective than no treatment, reducing progression to compensated and decompensated cirrhosis. The results remained true at stages F1 and F2 fibrosis and when considering the societal costs and the costs of AUD. Future studies should include prospective evaluations of screening strategies combined with early treatment, as many patients are diagnosed at advanced stages of ALD.

PMID 43050187
阅读全文 →
PubMedHepatology forum2026-11-17

Prevention of alcohol relapse in post-liver transplant patients with alcohol use disorder.

Elsawy Malak M, Bardak Ali Emre AE, Yildiz Eda E, Ozturk N Begum NB et al.

Alcohol-associated liver disease has become the most common reason for liver transplantation (LT) in many regions, including the US. This shift reflects the declining hepatitis C-related LTs and rising prevalence of harmful alcohol use, which increased substantially, especially during COVID-19 pandemic. Post-LT alcohol relapse leads to poor clinical outcomes, including medication non-adherence, graft dysfunction (steatosis and alcohol-related hepatitis), recurrent cirrhosis, and decreased overall survival. For patients with severe alcohol-associated hepatitis, early or expedited LT can offer a survival advantage in carefully selected candidates compared with traditional approaches requiring six months of pre-LT abstinence, without a substantial increase in hazardous relapse. Pre-LT risk assessment is essential for the candidate selection and combines psychosocial factors with validated tools such as Stanford Integrated Psychosocial Assessment for Transplantation, Hopkins psychosocial scale, sustained alcohol use post-LT, harmful alcohol use post-LT, and high-risk alcoholism relapse. Post-LT monitoring utilizing direct biomarkers (e.g., phosphatidylethanol, ethyl glucuronide) with indirect markers of alcohol-use to widen the detection window and capture both low-level and heavy use should be considered. Optimal management of alcohol-use disorder (AUD) relies on combining pharmacologic and psychosocial interventions. Among pharmacologic options, naltrexone and acamprosate are considered first-line options, whereas disulfiram is less commonly used after LT given concerns about its drug interactions. Psychosocial aspects of the management are as important as the pharmacologic aspects to maintain abstinence and reduce relapse risk. Potential barriers to participation, such as hepatic decompensation, hepatic encephalopathy, or logistical challenges, should also be recognized and addressed. This narrative review summarizes current management strategies for AUD with emphasis on the post-LT setting.

PMID 43041983
阅读全文 →
PubMedClinical and experimental dermatology2026-11-13

Oral Naltrexone in Hailey-Hailey Disease: Review of the Current Clinical Evidence.

Xuereb Hannah H, Boffa Michael J MJ

Hailey-Hailey disease (HHD) is a rare, chronic dermatosis that has a significant negative impact on patients' quality of life due to recurrent painful erosions in intertriginous areas. Despite various available therapies, treatment remains challenging. Naltrexone, an opioid receptor antagonist, represents an emerging potential therapeutic option in refractory HHD. This review aimed to summarise the current evidence on efficacy and safety of naltrexone as a treatment for HHD, focusing on therapeutic outcomes, adverse effects, and clinical applicability in adult patients. A literature search was conducted for publications available up to December 2025. A total of 17 publications (11 case reports, 5 case series and 1 retrospective study) met the inclusion criteria, representing a total of 47 patients. Most patients had refractory HHD with poor response to conventional therapies. Treatment resulted in improvement - defined as clearance of lesions or reduction of affected body surface area (BSA), with no reported relapse - in 64% of patients (30 of 47). Thirty-eight patients received naltrexone monotherapy whilst 9 received other treatment concomitantly. Of the monotherapy patients 25 (65.8%) reported clinical improvement, compared with 5 of 9 (55.6%) receiving concomitant therapy. Using a more stringent definition of response (complete clearance or ≥70% improvement), 24 of 47 patients (51.1%) met the criterion, including 21 of 38 (55.3%) receiving monotherapy. Complete clearance was reported in 11 patients (23.4%). These proportions reflect outcomes reported in published cases and should not be interpreted as true response rates. Relapse was reported both during continued treatment and following withdrawal, highlighting uncertainty regarding the durability of response. Adverse effects were minimal, most commonly nausea, dizziness and vivid dreams and were reported in 15% of patients (7 of 47). Current reports suggest that naltrexone may represent a safe novel treatment option for patients with refractory HHD. However, this is based solely on very low level evidence, limited by publication bias, heterogeneous outcome definitions, incomplete reporting of seasonality, and concomitant treatments. Prospective controlled studies with standardised outcome measures, long-term follow-up across different seasons, and careful reporting of concomitant therapies are required to establish the efficacy, optimal dosing and long-term safety of naltrexone in HHD.

PMID 43023382
阅读全文 →
PubMedJournal of psychiatric practice2026-11-11

The Complex Relationship Between ADHD and Alcohol Use Disorder: A Narrative Review.

Skryabin Valentin V, Makartseva Polina P, Sokolova Svetlana S, Martinotti Giovanni G

The comorbidity between attention-deficit/hyperactivity disorder (ADHD) and alcohol use disorder (AUD) presents significant clinical challenges, with ADHD increasing the risk of early alcohol initiation, more severe drinking patterns, and poorer treatment outcomes. This review explores the epidemiological, neurobiological, and psychosocial mechanisms underlying ADHD-AUD comorbidity, highlighting the role of impulsivity, executive dysfunction, and dopaminergic dysregulation in increasing susceptibility to alcohol dependence. We discuss the challenges of diagnosing ADHD in individuals with AUD, given overlapping cognitive impairments and alcohol withdrawal effects that may mimic ADHD symptoms. We also evaluate current pharmacological and behavioral treatment strategies, emphasizing the need for integrated approaches to care that balance ADHD symptom management with relapse prevention in patients with AUD. Although stimulant medications improve impulse control and executive function, their role in preventing alcohol misuse remains uncertain, necessitating careful monitoring. Nonstimulant options such as atomoxetine and guanfacine, alongside anti-craving agents like naltrexone, offer alternative treatment pathways. Cognitive-behavioral therapy, mindfulness-based interventions, and motivational enhancement therapy show promise in addressing ADHD-related alcohol use behaviors. Given the limited long-term data on ADHD treatment in populations with AUD, future research should focus on longitudinal studies, neuroimaging biomarkers, and personalized medicine approaches to optimize clinical management. Expanding ADHD screening in addiction settings and implementing policy changes to improve treatment access will be crucial for enhancing patient outcomes.

PMID 43013859
阅读全文 →
PubMedAmerican journal of preventive medicine2026-11-11

Temporal trends and disparities in initiation of medications for opioid use disorder among Medicaid enrollees by race and Medicaid expansion status.

Li Yujia Y, Qato Danya M DM, Rizk John G JG, Pathan Uzma U et al.

Prior research suggests Black and Hispanic individuals are less likely to receive medications for opioid use disorder (MOUD) compared to White individuals. Little is known about how these disparities in timely treatment initiation evolved during a period of major policy changes, including Medicaid expansion. The objective of this study is to examine temporal trends in timely MOUD initiation following opioid use disorder (OUD) diagnosis among Medicaid enrollees across racial and ethnic groups, and assess whether these existing disparities have changed over time. This serial cross-sectional study used 2015-2018 Medicaid enrollment and claims data from 18 U.S. states. Adults aged 18-64 years with an incident OUD diagnosis and continuous Medicaid enrollment were included. The primary outcome was timely MOUD initiation, defined as receipt of buprenorphine, methadone, or naltrexone within 90 days of OUD diagnosis. Racial and ethnic disparities in timely MOUD initiation were assessed annually using adjusted logistic regression models accounting for sociodemographic and clinical characteristics, with analyses stratified by state-level Medicaid expansion status. Of 295,049 Medicaid enrollees with OUD, 20.9% initiated MOUD within 90 days, increasing from 16.6% in 2015 to 27.0% in 2018 (p<0.001). Black enrollees had substantially lower odds of initiation compared to White enrollees across all years (adjusted odds ratio [aOR] 0.45, [0.42-0.48] in 2015 to 0.49 [0.47-0.52] in 2018). Hispanic enrollees had comparable odds in 2015 (aOR 1.07 [0.99-1.14]) but significantly lower odds by 2018 (aOR 0.84 [0.78-0.90]) compared to White enrollees. Disparities were observed in both expansion and non-expansion states yet were more pronounced in non-expansion settings. Timely MOUD initiation among Medicaid enrollees increased from 2015 to 2018, but disparities persisted and, for Hispanic enrollees, widened. Findings highlight the need for efforts beyond insurance coverage to address structural barriers and provide culturally tailored approaches to promote equitable MOUD utilization.

PMID 43014456
阅读全文 →
PubMedFrontiers in public health2026-11-11

Fifty years at the addiction bench and bedside: from withdrawal syndromes to adaptive brain states.

Gold Mark S MS

Over the past half-century, addiction medicine has moved from moral and symptom-based explanations toward a neuroscience of adaptation, learning, motivation, and recovery. This Perspective uses several linked translational programs-opioid withdrawal and the locus coeruleus, cocaine dependence and dopamine, environmental drug exposure, physician health, and food reward-to illustrate how observations at the bedside can generate mechanistic studies and how laboratory findings can, in turn, change treatment and public health. LC stimulation produced signs and symptoms that looked to me like opioid withdrawal. So, we thought that noradrenergic hyperactivity in opioid withdrawal caused symptoms, and while methadone or morphine could treat these, we could also treat them with a non-opioid, clonidine. Earlier noradrenergic interventions had been attempted with limited clinical success. Our work provided the first hypothesis-driven, double-blind, placebo-controlled demonstration that a non-opioid medication could suppress the acute human opioid withdrawal syndrome. This mechanism-based treatment was greeted with considerable interest because some clinicians had assumed that any medication capable of reversing opioid withdrawal distress must itself be an opioid. Clonidine and later lofexidine did just that and facilitated transition to naltrexone. Recognition that cocaine could produce compulsive use without a dramatic physical withdrawal syndrome helped shift the field toward reward circuitry, craving, pathological attraction, anhedonia, and relapse. Studies of tobacco, cannabis, and opioid smoke broadened prevention by showing that involuntary second- and third-hand exposure can be biologically detected and, most clearly for tobacco, can produce biologically meaningful effects. Third-hand exposure refers to residual drug-related contaminants that persist on indoor surfaces, dust, clothing, or other materials after active smoking has ended. Contemporary work on neuromodulation, exercise, psychedelics, and GLP-1 metabolic-reward pathways extends the same translational logic. Addiction is best understood as an acquired adaptive brain state supported by anti-survival or bad learning, development, and environment; recovery is active neurobehavioral relearning, not simply detoxification or drug clearance. Public health should therefore join brain sciences, work to delay initiation, identify emerging risk before a severe substance use disorder develops, prevent involuntary exposure, and provide rapid access to mechanism-based treatment, recovery-supportive environments, and outcomes measured over 5 years or longer.

PMID 43011373
阅读全文 →

注册免费账户还可查看另外 8740 篇文献

免费注册查看全部文献 →

了解更多naltrexone